



GP 1646
RECEIVED
JAN 11 2001

PATENT APPLICATION
ATTORNEY DOCKET 27129/33638A (now 29715/33638A)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ammons et al.

Serial No: 09/416,828

Filed: October 12, 1999

For: "Method of Treating Conditions
Associated with Intestinal
Ischemia/Reperfusion

Group Art Unit: 1646

Examiner: not assigned

) I hereby certify that this paper is being
) deposited with the United States Postal
) Service as First Class Mail, postage prepaid
) in an envelope addressed to: Commissioner
) for Patents, Washington, D.C. 20231, on
) this date:

) January 9, 2001

) Li-Hsien Rin-Laures
) Li-Hsien Rin-Laures, M.D.

) Registration No. 33,547

#4
AQJ
1/11/01

RE-TRANSMITTAL OF SEQUENCE LISTING STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action and Notice to Comply with sequence listing requirements mailed December 18, 2000, enclosed is a copy of the Sequence Listing Statement filed with the application.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN

By:

Li-Hsien Rin-Laures
Li-Hsien Rin-Laures, M.D.
Registration No. 33,547
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

January 9, 2001
Chicago, Illinois

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(i).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: See MPEP 2422.05 for transferring the computer readable form of sequence listing from a parent or previously filed application in which a complying computer readable form had been filed.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patent In Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase Patent In Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE